| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Protein HID1, Down-regulated in multiple cancers 1, HID1 domain-containing protein, Protein hid-1 homolog, HID1, C17orf28, DMC1 |
| Entrez GeneID | 283987 |
| WB Predicted band size | 88.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CQ028 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 567-595 amino acids from the C-terminal region of human CQ028. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CQ028抗体的虚构参考文献示例(仅供参考，实际文献需通过学术数据库验证)：
---
1. **标题**：CQ028 Antibody Targets HER2-Positive Breast Cancer via PI3K/AKT Pathway Inhibition
**作者**：Zhang, L. et al.
**摘要**：研究报道了CQ028抗体通过特异性结合HER2受体，抑制下游PI3K/AKT信号通路，显著降低乳腺癌细胞增殖和转移，为HER2阳性乳腺癌的靶向治疗提供新策略。
2. **标题**：CQ028 Enhances Chemotherapy Efficacy in Ovarian Cancer through Antibody-Drug Conjugation
**作者**：Wang, Y. et al.
**摘要**：CQ028抗体与拓扑异构酶抑制剂偶联，可精准靶向卵巢癌细胞，增强化疗药物递送效率，并在小鼠模型中实现肿瘤体积缩小和生存期延长。
3. **标题**：CQ028 Synergizes with PD-1 Blockade in Immune Checkpoint Therapy
**作者**：Li, X. et al.
**摘要**：CQ028抗体通过调节肿瘤微环境中的T细胞活性，与抗PD-1疗法联合使用，显著提升黑色素瘤模型的抗肿瘤免疫应答，提示其联合治疗潜力。
4. **标题**：CQ028-Loaded Nanoparticles for Targeted Drug Delivery in Solid Tumors
**作者**：Chen, R. et al.
**摘要**：基于CQ028抗体的纳米递送系统可穿透实体瘤屏障，提高药物在肿瘤组织中的富集，减少脱靶毒性，为精准治疗提供新思路。
---
**注意**：以上内容为示例性虚构文献，实际研究中可能不存在同名抗体或相关论文。建议通过**PubMed、Google Scholar**等平台，以“CQ028 antibody”为关键词检索最新实证研究，并确认抗体名称的正确性(如是否为商业化抗体的编号或研究代号)。如需进一步协助筛选文献，请提供更多上下文信息。
The CQ028 antibody is a monoclonal antibody developed for research and potential therapeutic applications, primarily targeting specific antigens associated with disease pathways. While detailed public information on CQ028 remains limited, it likely belongs to a class of biologics engineered to bind selectively to cell surface receptors or soluble proteins involved in pathological processes, such as cancer progression, autoimmune disorders, or infectious diseases. Antibodies like CQ028 are often humanized or fully human to minimize immunogenicity and enhance clinical compatibility.
Its development may involve hybridoma technology or recombinant DNA methods, enabling precise antigen recognition. Preclinical studies possibly focus on validating its binding affinity, specificity, and functional effects—e.g., blocking ligand-receptor interactions, inducing antibody-dependent cellular cytotoxicity (ADCC), or delivering conjugated drugs. Potential applications could include oncology (targeting tumor-associated antigens), immunomodulation (e.g., checkpoint inhibitors), or diagnostic imaging.
Collaborations between academic labs and biotech firms might drive its optimization and scaling. As with many investigational antibodies, challenges include ensuring stability, bioavailability, and safety in vivo. Further characterization and clinical trials would be necessary to define its therapeutic efficacy and commercial viability. CQ028 represents a growing trend in precision medicine, aiming to offer tailored treatments with reduced off-target effects compared to conventional therapies.
×
